Imunon, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IMNN in the last 30 days.
See all $IMNN insider activity →Imunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and t
Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.
Imunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Compensation Committee and the Board of Directors of Imunon, Inc. (the “Company”), as applicable, approved compensatory
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IMNN (Imunon, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IMNN coverage spans corporate actions, technology and earnings.
The capital raise adds cash but also dilutes existing shareholders; short‑term price may see modest upside as financing is confirmed.
Clinical readouts and faster Phase 3 enrollment are positive, but the need for additional capital and ongoing cash burn keep risk elevated.
The filing is a routine executive compensation update via share issuance elections, with limited direct fundamental impact but potential near-term trading sensitivity around dilution expectations.
Faster Phase 3 enrollment and positive interim Phase 2 read-through (OS and MRD/ctDNA) can improve probability-weighted timelines and risk perception.
Positive clinical execution and added cash runway reduce near-term funding risk, supporting a bullish risk-reward for IMNN-001.
AlphAI scores every news story that mentions IMNN with an AI model for sentiment and relevance, and aggregates insider trades from Imunon, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Imunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and t
2 min readImunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.
7 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Compensation Committee and the Board of Directors of Imunon, Inc. (the “Company”), as applicable, approved compensatory
2 min readIMUNON (IMNN) reported Q2 2026 results and an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed advanced ovarian cancer. The company said enrollment is progressing faster than expected and expects completion in 1H 2029. It cited Phase 2 OVATION 2 median OS of 45.1 vs 30.4 months and MRD/ctDNA clearance improvements. Net loss was $2.8M.
4 min readImunon, Inc. (IMNN) said its OVATION 3 Phase III enrollment is ahead of plan and that IMNN-001 has strong safety and efficacy data, according to an Aug. 11, 2026 Q2 2026 audio transcript. The company reported stable financials and a $10 million financing to extend its runway through year-end 2026.
1 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enroll
6 min readIMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.
4 min readImunon said its IMNN-001 plus standard chemotherapy and bevacizumab lowered surgical MRD-positive rates in a multi-site advanced ovarian cancer study, 44% vs 67%, and improved ctDNA clearance, 87.5% vs 62.5%. The company also cited prior OVATION 2 results with median OS up 14.7 months. Imunon shares rose to $1.91 premarket.
5 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000749647 0000749647 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report
3 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 EXHIBIT 10.1 IMUNON, INC. THE 2018 STOCK INCENTIVE PLAN AS AMENDED AS OF JUNE 16, 2026 I. INTRODUCTION 1.1 Purposes . The purposes of the IMUNON, INC. 2018 Stock Incentive Plan (this “ Plan ”) are (i) to align the interests of the Company’s stockholde
6 min read
